Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2307575 | 0.93 | CA2 (0.52) | CA2CYP4A11LTA4HEPHX2SPHK2 | |
| SCHEMBL1264259 | 0.91 | CA2 (0.53) | CA2CYP4A11SPHK2SPHK1CYP4F2 | |
| SCHEMBL2314633 | 0.91 | CA2 (0.53) | CA2CYP4A11SPHK2SPHK1CYP4F2 | |
| SCHEMBL7596180 | 0.91 | CA2 (0.53) | CA2CYP4A11SPHK2SPHK1CYP4F2 | |
| SCHEMBL15352379 | 0.91 | CA2 (0.53) | CA2CYP4A11SPHK2SPHK1CYP4F2 | |
| SCHEMBL16415200 | 0.91 | CA2 (0.53) | CA2CYP4A11SPHK2SPHK1CYP4F2 | |
| SCHEMBL16414507 | 0.91 | CA2 (0.53) | CA2CYP4A11SPHK2SPHK1CYP4F2 | |
| SCHEMBL1263897 | 0.91 | CA2 (0.53) | CA2CYP4A11SPHK2SPHK1CYP4F2 | |
| SCHEMBL16414974 | 0.91 | CA2 (0.53) | CA2CYP4A11SPHK2SPHK1CYP4F2 | |
| SCHEMBL16414735 | 0.91 | CA2 (0.53) | CA2CYP4A11SPHK2SPHK1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955244-A | Method for preparing primary alcohol by homogeneously catalyzing and reducing carboxylic acid derivative by using N-heterocyclic carbene copper complex | 延安大学 | 2024-11-15 | — | — | CN | disclosed |
| US-20230135188-A1 | FE/CU-MEDIATED KETONE SYNTHESIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-05-04 | — | — | US | disclosed |
| US-11498892-B2 | Fe/Cu-mediated ketone synthesis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210179522-A9 | FE/CU-MEDIATED KETONE SYNTHESIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3020715-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-3040332-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20200165183-A1 | FE/CU-MEDIATED KETONE SYNTHESIS | President and Fellows of Flarvard College (US) | 2020-05-28 | — | — | US | disclosed |
| EP-2990404-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-05-27 | — | — | EP | disclosed |
| EP-3029030-B1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| WO-2008106226-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106204-A1 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X-PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008044667-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | WO | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| US-4175544-A | X-RAYS OF BODY FOR MEDICAL DIAGNOSIS | Lafayette Pharmacal Inc. (US) | 1979-11-27 | — | — | US | disclosed |
| US-4125554-A | Iodinated thiolcarbonates and method for use as radiographic contrast agents | ALCON LABORATORIES, INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4022814-A | Iodine containing organic carbonates for use as radiographic agents | LAFAYETTE PHARMACAL, INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179522-A9 | FE/CU-MEDIATED KETONE SYNTHESIS | TKT, COASY, FECH | CA2 1164/4885CYP4A11 423/4885LTA4H 3714/4885 |
| US-20200165183-A1 | FE/CU-MEDIATED KETONE SYNTHESIS | TKT, COASY, FECH | CA2 1164/4885CYP4A11 423/4885LTA4H 3714/4885 |
| US-11498892-B2 | Fe/Cu-mediated ketone synthesis | TKT, COASY, FECH | CA2 1164/4885CYP4A11 423/4885LTA4H 3714/4885 |
| US-20230135188-A1 | FE/CU-MEDIATED KETONE SYNTHESIS | TKT, COASY, FECH | CA2 1164/4885CYP4A11 423/4885LTA4H 3714/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | CA2 1149/4885CYP4A11 183/4885LTA4H 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.